Home Categories API sitagliptin
A7497212

sitagliptin , 97% , 486460-32-6

CAS NO.:486460-32-6

Empirical Formula: C16H15F6N5O

Molecular Weight: 407.31

MDL number: MFCD09838015

EINECS: 690-730-1

Pack Size Price Stock Quantity
100MG RMB111.20 In Stock
1G RMB194.40 In Stock
5g RMB594.40 In Stock
25g RMB1690.40 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 114.1-115.7 °C
Boiling point: 529.9±60.0 °C(Predicted)
Density  1.61±0.1 g/cm3(Predicted)
storage temp.  Store at -20°C
solubility  DMSO : ≥ 50 mg/mL (122.76 mM)
pka 7.20±0.10(Predicted)
form  Solid
color  White to off-white
InChI InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey MFFMDFFZMYYVKS-SECBINFHSA-N
SMILES C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F
CAS DataBase Reference 486460-32-6(CAS DataBase Reference)
EPA Substance Registry System 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (486460-32-6)

Description and Uses

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.

Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-?diabetes, impaired glucose tolerance, hepatitis, and?/or inflammatory liver disease.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P305+P351+P338
Hazardous Substances Data 486460-32-6(Hazardous Substances Data)

RELATED PRODUCTS